Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Grows By 106.5%

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 6,630,017 shares, an increase of 106.5% from the June 30th total of 3,211,049 shares. Approximately 7.6% of the company’s stock are sold short. Based on an average daily volume of 3,660,812 shares, the days-to-cover ratio is currently 1.8 days.

Context Therapeutics Stock Performance

CNTX traded down $0.01 during trading on Thursday, reaching $0.61. 627,575 shares of the stock were exchanged, compared to its average volume of 1,815,264. The stock’s 50 day moving average price is $1.16 and its two-hundred day moving average price is $1.96. Context Therapeutics has a twelve month low of $0.55 and a twelve month high of $3.62. The stock has a market cap of $55.86 million, a P/E ratio of -1.45 and a beta of 1.75.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. Equities research analysts predict that Context Therapeutics will post -0.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CNTX has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Finally, Maxim Group dropped their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Context Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Octagon Capital Advisors LP acquired a new position in Context Therapeutics during the first quarter worth approximately $13,755,000. Millennium Management LLC bought a new position in shares of Context Therapeutics during the 4th quarter worth approximately $3,824,000. Marshall Wace LLP raised its stake in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the period. Seven Fleet Capital Management LP acquired a new stake in Context Therapeutics during the 1st quarter valued at $500,000. Finally, Renaissance Technologies LLC lifted its holdings in Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.